Evaluation of patients with HIV and hepatitis co-infection, 5 years of experience

Suzan Şahin; Bülent Kaya

Makale detayları

Evaluation of patients with HIV and hepatitis co-infection, 5 years of experience

Yazarlar:

Suzan Şahin | Bülent Kaya

Yayıncı:

Eskişehir Osmangazi University

Ana Başlıklar:

Bulaşıcı Hastalıklar

Dergi:

Osmangazi Tıp Dergisi Vol.46 Issue 4, pp.521-527

Belge Tipi:

Makale

Yayın Tarihi:

7/2024

Belge Dili:

Türkçe

Document ID (Org No.):

2001314135

pISSN:

1305-4953

Anahtar kelimeler:

Özet:

 This study aimed to see the prevalence of hepatitis in patients followed in our outpatient clinic due to Human Immunodeficiency Virus HIV infection. Between January 2018 and December 2022, 530 HIV-positive patients followed in the Infectious Diseases and Clinical Microbiology outpatient clinic of Dr. Lütfi Kırdar Kartal City Hospital were retrospectively examined in terms of hepatitis serology. At the time of initial admission, patients were evaluated with hepatitis A virus HAV immunoglobulin Ig G, hepatitis B surface antigen HBsAg, hepatitis B core antibody anti-HBc, antibody against hepatitis B surface antigen anti-HBs and hepatitis C virus antibody anti HCV. Four hundred twelve 77.8 patients were immune to hepatitis A infection. HBsAg positivity was detected in 18 3.4 patients, anti-HBc and anti-HBs positivity was detected in 73 13.8 patients, and isolated anti-HBc positivity was present in 47 8.9 patients. Anti-HBs positivity developed in 180 34.0 patients after vaccination. There were 212 40.0 patients who had never exposed to Hepatitis B. Four 0.7 patients were anti-HCV positive. Screening every HIV positive patient who begins follow-up and treatment for hepatitis B virus HBV and hepatitis C virus HCV, selecting appropriate treatments to prevent cirrhosis and possible liver cancer risk in patients with HIVHBV or HIVHCV co-infection is crucial, It is important to vaccinate those who are not immune to HBV, to determine immunity against hepatitis A, which can be fulminant when transmitted outside the pediatric age group, and to ensure that they are vaccinated when necessary.

 This study aimed to see the prevalence of hepatitis in patients followed in our outpatient clinic due to Human Immunodeficiency Virus HIV infection. Between January 2018 and December 2022, 530 HIV-positive patients followed in the Infectious Diseases and Clinical Microbiology outpatient clinic of Dr. Lütfi Kırdar Kartal City Hospital were retrospectively examined in terms of hepatitis serology. At the time of initial admission, patients were evaluated with hepatitis A virus HAV immunoglobulin Ig G, hepatitis B surface antigen HBsAg, hepatitis B core antibody anti-HBc, antibody against hepatitis B surface antigen anti-HBs and hepatitis C virus antibody anti HCV. Four hundred twelve 77.8 patients were immune to hepatitis A infection. HBsAg positivity was detected in 18 3.4 patients, anti-HBc and anti-HBs positivity was detected in 73 13.8 patients, and isolated anti-HBc positivity was present in 47 8.9 patients. Anti-HBs positivity developed in 180 34.0 patients after vaccination. There were 212 40.0 patients who had never exposed to Hepatitis B. Four 0.7 patients were anti-HCV positive. Screening every HIV positive patient who begins follow-up and treatment for hepatitis B virus HBV and hepatitis C virus HCV, selecting appropriate treatments to prevent cirrhosis and possible liver cancer risk in patients with HIVHBV or HIVHCV co-infection is crucial, It is important to vaccinate those who are not immune to HBV, to determine immunity against hepatitis A, which can be fulminant when transmitted outside the pediatric age group, and to ensure that they are vaccinated when necessary.

 This study aimed to see the prevalence of hepatitis in patients followed in our outpatient clinic due to Human Immunodeficiency Virus HIV infection. Between January 2018 and December 2022, 530 HIV-positive patients followed in the Infectious Diseases and Clinical Microbiology outpatient clinic of Dr. Lütfi Kırdar Kartal City Hospital were retrospectively examined in terms of hepatitis serology. At the time of initial admission, patients were evaluated with hepatitis A virus HAV immunoglobulin Ig G, hepatitis B surface antigen HBsAg, hepatitis B core antibody anti-HBc, antibody against hepatitis B surface antigen anti-HBs and hepatitis C virus antibody anti HCV. Four hundred twelve 77.8 patients were immune to hepatitis A infection. HBsAg positivity was detected in 18 3.4 patients, anti-HBc and anti-HBs positivity was detected in 73 13.8 patients, and isolated anti-HBc positivity was present in 47 8.9 patients. Anti-HBs positivity developed in 180 34.0 patients after vaccination. There were 212 40.0 patients who had never exposed to Hepatitis B. Four 0.7 patients were anti-HCV positive. Screening every HIV positive patient who begins follow-up and treatment for hepatitis B virus HBV and hepatitis C virus HCV, selecting appropriate treatments to prevent cirrhosis and possible liver cancer risk in patients with HIVHBV or HIVHCV co-infection is crucial, It is important to vaccinate those who are not immune to HBV, to determine immunity against hepatitis A, which can be fulminant when transmitted outside the pediatric age group, and to ensure that they are vaccinated when necessary.

 Bu çalışmada Human Immunodeficiency Virus HIV infeksiyonu nedeniyle polikliniğimizde takip edilen hastalarda hepatit prevalansını görmek amaçlandı. Ocak 2018-Aralık 2022 yılları arasında Dr. Lütfi Kırdar Kartal Şehir Hastanesi Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji polikliniğinde takip edilen 530 HIV pozitif hasta hepatit serolojisi açısından retrospektif olarak incelendi. Hastalara ilk başvuru sırasında hepatit A virüs HAV immunglobulin Ig G, hepatit B yüzey antijeni HBsAg, hepatit B kor antikoru anti-HBc, hepatit B yüzey antijenine karşı antikor anti-HBs ve hepatit C virus antikoru anti HCV bakıldı. Hepatit A infeksiyonuna karşı 412 77.8 hastanın bağışıklığı mevcuttu. On sekiz 3.4 hastada HBsAg pozitifliği, 73 13.8 hastada anti-HBc ve anti-HBs pozitif tespit edildi, 47  8.9 hastada izole anti-HBc pozitifliği mevcuttu. Aşılama sonrası 180 34.0 hastada anti-HBs pozitifliği gelişmişti. Hepatit B ile hiç karşılaşmayan 212 40.0 hasta vardı. Dört 0.7 hastada anti HCV pozitifliği vardı. HIV pozitifliği ile takip ve tedavisine başlanan her hastanın hepatit B virüsü HBV ve hepatit C virüsü HCV açısından taranması, HIVHBV veya HIVHCV ko-infeksiyonu tespit edilen hastalarda sirozu ve olası karaciğer kanseri riskini önlemek için uygun tedavilerin seçilmesi, HBV ye karşı bağışıklığı olmayanların aşılanması, pediatrik yaş grubu dışında geçirildiğinde fulminan seyredebilen hepatit Aya karşı bağışıklığın tespiti, gereğinde aşılanmalarının sağlanması önemlidir.

Makale detayları

Evaluation of patients with HIV and hepatitis co-infection, 5 years of experience

Yazarlar:

Suzan Şahin | Bülent Kaya

Yayıncı:

Eskişehir Osmangazi University

Ana Başlıklar:

Bulaşıcı Hastalıklar

Dergi:

Osmangazi Tıp Dergisi Vol.46 Issue 4, pp.521-527

Belge Tipi:

Makale

Yayın Tarihi:

7/2024

Belge Dili:

Türkçe

Document ID (Org No.):

2001314135

pISSN:

1305-4953

Human Immunodeficiency Virus (HIV)

Hepatitis A

Hepatitis B

Hepatitis CHuman Immunodeficiency Virus (HIV)

Hepatit A

Hepatit B

Hepatit C

Sayı

Makale detayları

Yazarlar: Suzan Şahin | Bülent Kaya

Yayıncı: Eskişehir Osmangazi University

Ana Başlıklar: Bulaşıcı Hastalıklar

Dergi: Osmangazi Tıp Dergisi Vol.46 Issue 4, pp.521-527

Belge Tipi: Makale

Yayın Tarihi: 7/2024

Belge Dili: Türkçe

Document ID (Org No.): 2001314135

pISSN: 1305-4953

Sayı

Yazarlar:

Suzan Şahin | Bülent Kaya

Yayıncı:

Eskişehir Osmangazi University

Ana Başlıklar:

Bulaşıcı Hastalıklar

Dergi:

Osmangazi Tıp Dergisi Vol.46 Issue 4, pp.521-527

Belge Tipi:

Makale

Yayın Tarihi:

7/2024

Belge Dili:

Türkçe

Document ID (Org No.):

2001314135

pISSN:

1305-4953